

**Table S3.** Methods of aspirin compliance assessment

<b>Methods of Compliance assessment</b>	<b>No. of studies</b>
Case/prescription records	4 <sup>1-4</sup>
Light Transmission Aggregometry	3 <sup>5-7</sup>
Observed dosing/Inpatient population	11 <sup>7-17</sup>
Patient drug diary	1 <sup>18</sup>
Pill counts	14 <sup>14, 18-30</sup>
Questionnaires	6 <sup>20, 21, 31-34</sup>
Salicylic acid/aspirin metabolite quantification	2 <sup>35, 36</sup>
Sample analysis with in vitro aspirin/salicylic acid	3 <sup>37-39</sup>
Serum, plasma or urine Thromboxane B2 quantification	5 <sup>22, 23, 40-42</sup>
Verbal Enquiry/Interviews	38 <sup>1-4, 22-24, 27, 30, 41-69</sup>

**References for Table S3**

1. Lee PY, Chen WH, Ng W, Cheng X, Kwok JYY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *American Journal of Medicine*. 2005;118(7):723.
2. Dawson J, Quinn T, Lees KR, Walters MR, Dawson J, Quinn T, et al. Microembolic Signals and Aspirin Resistance in Patients with Carotid Stenosis : Microembolic Signals and Aspirin Resistance. *Cardiovascular Therapeutics*. 2012;30(4):234.
3. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. *Platelets*. 2008;19(2):119-24.

4. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. *Platelets*. 2005;16(5):269.
5. Chakroun T, Gerotziapas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100TM closure time: pivotal role of plasma von Willebrand factor. *British Journal of Haematology*. 2004;124(1):80.
6. Albert SG, Hasnain BI, Ritter DG, Joist JH, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. *Diabetes Res Clin Pract*. 2005;70(2):195-9.
7. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance in secondary stroke prevention. *Acta Neurologica Scandinavica*. 2006;113(1):31-5.
8. Glauser J, Emerman CL, Bhatt DL, Peacock WF, Glauser J, Emerman CL, et al. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. *The American Journal of Emergency Medicine*. 2010;28(4):440.
9. Jastrzębska M, Chełstowski K, Siennicka A, Clark J, Wódecka A, Nowacki P. Factors influencing Multiplate whole blood Impedance Platelet Aggregometry measurements, during aspirin treatment in acute ischemic stroke: A pilot study. *Blood Coagulation and Fibrinolysis*. 2013;24(8):830-8.
10. Rajec J, Kriska M, Vojtko R, Dukat A, Risnyovszki Z, Sapak M. Biochemical evaluation of the antiplatelet effect of aspirin in patients at different levels of cardiovascular risk. *Bratislavske lekarske listy*. 2008;109(4):160-3.
11. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. *The American Journal Of Cardiology*. 2005;95(8):973-5.
12. Williams M, Kickler T, Vaidya D, Ng, rsquo, alla L, et al. Evaluation of platelet function in aspirin treated patients with CAD. *Journal of Thrombosis and Thrombolysis*. 2006;21(3):241.
13. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H, Grundmann K, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. *Journal of neurology*. 2003;250(1):63.
14. Kovacs E, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin& the lack of aspirin resistance among healthy individuals. *Thrombosis Research*. 2013;131(4):320-4.
15. Yokoyama H, Mastumura T, Soeda S, Suzuki Y, Watanabe M, Kashiwakura E, et al. The evaluation method for antiplatelet effect of acetylsalicylic acid. *European Journal of Drug Metabolism and Pharmacokinetics*. 2014;39(4):327.

16. Bennett D, Yan B, MacGregor L, Eccleston D, Davis SM, Bennett D, et al. A pilot study of resistance to aspirin in stroke patients. *Journal of Clinical Neuroscience*. 2008;15(11):1204.
17. Zheng AS, Churilov L, Colley RE, Goh C, Davis SM, Yan B, et al. Association of Aspirin Resistance With Increased Stroke Severity and Infarct Size. *JAMA Neurology*. 2013;70(2):208.
18. Shen H, Herzog W, Drolet M, Pakyz R, Newcomer S, Sack P, et al. Aspirin Resistance in Healthy Drug-Naive Men Versus Women (from the Heredity and Phenotype Intervention Heart Study). *The American Journal of Cardiology*. 2009;104(4):606.
19. Abaci A, Caliskan M, Bayram F, Yilmaz Y, Cetin M, Unal A, et al. A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100® and its predictors. *Platelets*. 2006;17(1):7.
20. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, et al. Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin. *Preventive cardiology*. 2010;13(2):56.
21. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, et al. Preventive cardiology: Relation Between Atherosclerosis Risk Factors and Aspirin Resistance in a Primary Prevention Population. *The American Journal of Cardiology*. 2006;98:774-9.
22. Neergaard-Petersen S, Ajjan R, Hvas A-M, Hess K, Larsen SB, Kristensen SD, et al. Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. *PLoS ONE*. 2013;8(8):1-8.
23. Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. *Thrombosis Research*. 2008;123(2):267-73.
24. Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals - Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. *Thrombosis and Haemostasis*. 2009;102(8):404-11.
25. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. *Journal of the American College of Cardiology*. 2009;53(8):667.
26. Tschopp M, Reinhart WH, Tschopp M, Reinhart WH, Tschopp M, Reinhart WH, et al. Platelet aggregation under high shear conditions during and after a 28-day administration of 100 mg acetylsalicylic acid in healthy volunteers. *Clinical hemorheology and microcirculation*. 2008;38(1):45.
27. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. *Stroke*. 1994;25(12):2331.
28. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, et al. Aspirin response and failure in cerebral infarction. *Stroke*. 1993;24(3):345.

29. Assadian A, Lax J, Meixner-Loicht U, Hagmüller GW, Bayer PM, Hübl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. *Journal Of Vascular Surgery*. 2007;45(6):1142-7.
30. Wong S, Ward CM, Appleberg M, Lewis DR, Wong S, Ward CM, et al. POINT OF CARE TESTING OF ASPIRIN RESISTANCE IN PATIENTS WITH VASCULAR DISEASE. *ANZ Journal of Surgery*. 2006;76(10):873.
31. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *The American Journal of Cardiology*. 2001;88(3):230.
32. Vaturi M, Vaduganathan M, Bental T, Solodky A, Kornowski R, Lev E. Relation of Aspirin Response to Age in Patients With Stable Coronary Artery Disease. *The American Journal of Cardiology*. 2013;112(2):212-6.
33. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB, Mehta SS, et al. Comparison of Aspirin Resistance in Type 1 Versus Type 2 Diabetes Mellitus. *The American Journal of Cardiology*. 2006;97(4):567.
34. Seok JI, Joo IS, Yoon JH, Choi YJ, Lee PH, Huh K, et al. Can aspirin resistance be clinically predicted in stroke patients? *Clinical neurology and neurosurgery*. 2008;110(2):110.
35. Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, et al. Aspirin Resistance and Compliance with Therapy. *Cardiovascular Therapeutics*. 2011;29(5):301-7.
36. Crowe B, Abbas S, Meany B, de Haan J, Cahill MR. Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina. *Seminars in thrombosis and hemostasis*. 2005;31(4):420-5.
37. Frelinger AL. Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-Dependent but Cyclooxygenase-1- and Cyclooxygenase-2-Independent Pathway: A 700-Patient Study of Aspirin Resistance. *Circulation*. 2006;113(25):2888.
38. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. *Journal of Thrombosis and Haemostasis*. 2008;6(12):2035-44.
39. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological Assessment of Aspirin Efficacy on Healthy Individuals: Heterogeneous Response or Aspirin Failure? *Stroke*. 2005;36(2):276.
40. Andersen K, Hurlen M, Arnesen H, Seljeflot I, Oslash, rg, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. *Thrombosis Research*. 2002;108(1):37.

41. Blann AD, Kuzniatsova N, Lip GY, Blann AD, Kuzniatsova N, Lip GY, et al. Vascular and platelet responses to aspirin in patients with coronary artery disease. *European Journal of Clinical Investigation*. 2013;43(1):91.
42. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? *American Heart Journal*. 2004;147(2):293.
43. Acikel S, Yildirim A, Aydinalp A, Bal U, Kaynar G, Ozin B, et al. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2009;20(6):427.
44. Can MM, Tanbo, a, brahim H, uuml, rky, et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. *Thrombosis Research*. 2010;125(4):e132.
45. Chakroun T, Addad F, Ben-Farhat M, Hamdi S, Gamra H, Ben-Hamda K, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. *Thrombosis Research*. 2007;121(3):413-8.
46. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2008;19(3):235.
47. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. *Thrombosis Research*. 2002;108(2-3):115.
48. Gulmez O, Yildirim A, Bal U, Konas ND, Aydinalp A, Demir O, et al. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2007;18(1):9.
49. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. *European Heart Journal*. 2007;28(14):1702-8.
50. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. France: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. *Thrombosis Research*. 2002;107:45-9.
51. Muir AR, McMullin MF, Patterson C, McKeown PP, Muir AR, McMullin MF, et al. Secondary prevention of coronary disease: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. *Heart*. 2009;95(15):16.

52. Narvaez I, Sagastagoitia JD, Vacas M, Saez Y, Lafita M, Monica S, et al. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. *Thrombosis Research*. 2007;120(5):671.
53. Ozben B, Tanrikulu AM, Ozben T, Caymaz O, Ozben B, Tanrikulu AM, et al. Aspirin Resistance in Hypertensive Patients. *Journal of clinical hypertension*. 2010;12(9):714.
54. Poulsen TS, Oslash, rgensen B, Korsholm L, Bj, Oslash, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. *Thrombosis Research*. 2007;119(5):555.
55. Poulsen TS, Kristensen S, Oslash, ren R, Korsholm L, Haghfelt T, et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. *Thrombosis Research*. 2007;120(4):477.
56. Tantry US, Bliden KP, Gurbel PA, Tantry US, Bliden KP, Gurbel PA. Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. *Journal of the American College of Cardiology*. 2005;46(9):1705.
57. Santos MT, Valles J, Lago A, Tembl J, aacute, nchez E, et al. Residual platelet thromboxane A&lt;sub&gt;2&lt;/sub&gt; and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. *Journal of Thrombosis and Haemostasis*. 2008;6(4):615.
58. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. *Acta Diabetol*. 2005;42(2):99-103.
59. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. *Journal of Thrombosis and Haemostasis*. 2006;4(6):1271.
60. Caron N, Rivard G, Michon N, Morin F, Pilon D, Montquin J, et al. Low-dose ASA response using the PFA-100 in women with high risk pregnancy. *Journal of Obstetrics and Gynaecology Canada* 2009;31(11):1022-7.
61. Rey E, Rivard G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? *European Journal of Obstetrics and Gynecology*. 2011;157:38-42.
62. Sullivan MHF, Elder MG. Changes in platelet reactivity following aspirin treatment for pre-eclampsia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 1993;100(6):542.
63. Heistein LC, Scott WA, Zellers TM, Fixler DE, Ramaciotti C, Journeycake JM, et al. Aspirin Resistance in Children with Heart Disease at Risk for Thromboembolism: Prevalence and Possible Mechanisms. *Pediatric Cardiology*. 2008;29(2):285.

64. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. *Clinical Neurology and Neurosurgery*. 2009;111(3):270-3.
65. Bruno A. Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction. *Stroke*. 2004;35(3):727.
66. Englyst NA, Horsfield G, Kwan J, Byrne CD, Englyst NA, Horsfield G, et al. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. *Journal of Cerebral Blood Flow and Metabolism*. 2008;28(6):1196.
67. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, et al. Aspirin Resistance: Possible Roles of Cardiovascular Risk Factors, Previous Disease History, Concomitant Medications and Haemorrheological Variables. *Drugs & Aging*. 2006;23(7):559.
68. Feher G, Koltai K, Kesmarky G, Toth K. Hemorheological background of acetylsalicylic acid resistance. *Clinical Hemorheology & Microcirculation*. 2008;38(3):143-52.
69. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E, Linnemann B, et al. Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. *Annals of hematology*. 2009;88(10):979.